scholarly journals Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort

2010 ◽  
Vol 12 (5) ◽  
pp. R166 ◽  
Author(s):  
Shervin Assassi ◽  
Roozbeh Sharif ◽  
Robert E Lasky ◽  
Terry A McNearney ◽  
Rosa M Estrada-Y-Martin ◽  
...  
Keyword(s):  
Longitudinal Study ◽  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Prospective Longitudinal Study ◽  
Prospective Longitudinal ◽  
Early Systemic Sclerosis

scholarly journals Predictors of Fatigue Severity in Early Systemic Sclerosis: A Prospective Longitudinal Study of the GENISOS Cohort

PLoS ONE ◽  
2011 ◽  
Vol 6 (10) ◽  
pp. e26061 ◽  
Author(s):  
Shervin Assassi ◽  
Astrud L. Leyva ◽  
Maureen D. Mayes ◽  
Roozbeh Sharif ◽  
Deepthi K. Nair ◽  
...  
Keyword(s):  
Longitudinal Study ◽  
Systemic Sclerosis ◽  
Prospective Longitudinal Study ◽  
Fatigue Severity ◽  
Prospective Longitudinal ◽  
Early Systemic Sclerosis

Tocilizumab Prevents Progression of Early Systemic Sclerosis Associated Interstitial Lung Disease

2021 ◽  
Author(s):  
David Roofeh ◽  
Celia J F Lin ◽  
Jonathan Goldin ◽  
Grace Hyun Kim ◽  
Daniel E Furst ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Early Systemic Sclerosis

Incidence and predictors of interstitial lung disease (ILD) in Thai patients with early systemic sclerosis: Inception cohort study

2015 ◽  
Vol 26 (4) ◽  
pp. 588-593 ◽  
Author(s):  
Suparaporn Wangkaew ◽  
Juntima Euathrongchit ◽  
Pittaporn Wattanawittawas ◽  
Nuntana Kasitanon ◽  
Worawit Louthrenoo
Keyword(s):  
Cohort Study ◽  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Inception Cohort ◽  
Early Systemic Sclerosis

scholarly journals A Prospective Longitudinal Study Evaluating The Influence of Immunosuppressives and Other Factors On COVID-19 in Autoimmune Rheumatic Diseases

2021 ◽  
Author(s):  
Abhishek Patil ◽  
Chanakya K ◽  
Padmanabha Shenoy ◽  
Chandrashekara S ◽  
Vikram Haridas ◽  
...  
Keyword(s):  
Risk Factors ◽  
Longitudinal Study ◽  
General Population ◽  
Lung Disease ◽  
Rheumatic Diseases ◽  
Case Fatality ◽  
Geographic Region ◽  
Prospective Longitudinal Study ◽  
Autoimmune Rheumatic Diseases ◽  
Prospective Longitudinal

Abstract Background We conducted this study to identify the influence of prolonged use of hydroxychloroquine(HCQ), glucocorticoids (GC) and other immunosuppressants (IS) on occurrence and outcome of COVID-19 in patients with autoimmune rheumatic diseases (AIRDs). Methods This was a prospective, multicenter, non-interventional longitudinal study across 15 specialist rheumatology centers. Consecutive AIRD patients on treatment with immunosuppressants were recruited and followed up longitudinally to assess parameters contributing to development of COVID-19 and its outcome. Results COVID-19 occurred in 314(3.45%) of 9212 AIRD patients during a median follow up of 177 (IQR 129,219) days. Long term HCQ use had no major impact on the occurrence or the outcome of COVID-19. Glucocorticoids in moderate dose (7.5-20mg/day) conferred higher risk (RR = 1.72) of infection. Among the IS, Mycophenolate mofetil (MMF), Cyclophosphamide (CYC) and Rituximab (RTX) use was higher in patients with COVID 19. However, the conventional risk factors such as male sex (RR = 1.51), coexistent diabetes mellitus (RR = 1.64), pre-existing lung disease (RR = 2.01) and smoking (RR = 3.32) were the major contributing risk factors for COVID-19. Thirteen patients (4.14%) died, the strongest risk factor being pre-existing lung disease (RR = 6.36, p = 0.01). Incidence ((17.5 vs 5.3 per 1 lakh (Karnataka) and 25.3 vs 7.9 per 1 lakh(Kerala) ) and case fatality (4.1% vs 1.3 % (Karnataka) and 4.3% vs 0.4% (Kerala)) rate of COVID-19 was significantly higher (p < 0.001) compared to the general population of the corresponding geographic region. Conclusions Immunosuppressants have a differential impact on the risk of COVID-19 occurrence in AIRD patients. Older age, males, smokers, hypertensive, diabetic and underlying lung disease contributed to higher risk. The incidence rate and the case fatality rate in AIRD patients is much higher than that in the general population.

SAT0478 Incidence And Predictors of Interstitial Lung Disease (ILD) in Early Systemic Sclerosis Patients: Inception Cohort Study

2015 ◽  
Vol 74 (Suppl 2) ◽  
pp. 833.2-833
Author(s):  
S. Wangkaew ◽  
J. Euathrongchit ◽  
P. Watanawittawas ◽  
N. Kasitanon ◽  
S. Puntana ◽  
...  
Keyword(s):  
Cohort Study ◽  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Inception Cohort ◽  
Early Systemic Sclerosis

OP0237 Lung ultrasound for the screening of interstitial lung disease in very early systemic sclerosis

2013 ◽  
Vol 71 (Suppl 3) ◽  
pp. 136.1-136
Author(s):  
L. Gargani ◽  
T. Barskova ◽  
M.L. Conforti ◽  
S. Guiducci ◽  
C. Bruni ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Lung Ultrasound ◽  
Early Systemic Sclerosis

Lung ultrasound for the screening of interstitial lung disease in very early systemic sclerosis

2012 ◽  
Vol 72 (3) ◽  
pp. 390-395 ◽  
Author(s):  
Tatiana Barskova ◽  
Luna Gargani ◽  
Serena Guiducci ◽  
Silvia Bellando Randone ◽  
Cosimo Bruni ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Lung Ultrasound ◽  
Early Systemic Sclerosis

scholarly journals Does C-Reactive Protein Predict the Long-Term Progression of Interstitial Lung Disease and Survival in Patients With Early Systemic Sclerosis?

2013 ◽  
Vol 65 (8) ◽  
pp. 1375-1380 ◽  
Author(s):  
Xiaochun Liu ◽  
Maureen D. Mayes ◽  
Claudia Pedroza ◽  
Hilda T. Draeger ◽  
Emilio B. Gonzalez ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Early Systemic Sclerosis

Immunosuppression use in early systemic sclerosis may be increasing over time

2021 ◽  
pp. 239719832110009
Author(s):  
Ryan Park ◽  
Tatiana Nevskaya ◽  
Murray Baron ◽  
Janet E Pope
Keyword(s):  
Mycophenolate Mofetil ◽  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Immunosuppressive Therapy ◽  
Skin Score ◽  
The Past ◽  
Modified Rodnan Skin Score ◽  
Diffuse Cutaneous Systemic Sclerosis ◽  
Early Systemic Sclerosis

Background: Immunosuppression remains the main treatment for progressing skin involvement, interstitial lung disease and inflammatory joint or muscle disease in systemic sclerosis. This study investigated the pattern and trends in immunosuppressive agents used in early systemic sclerosis (diagnosed before and after 2007) to determine whether the changes in the preferred type, timing and combination of immunosuppression took place over the past decade. Methods: In total, 397 Canadian Scleroderma Research Group database patients (183 diffuse cutaneous systemic sclerosis and 214 limited cutaneous systemic sclerosis) who had baseline and follow-up visits within 3 years (mean: 1.8 ± 0.8) after disease onset were included: 82% females, age at diagnosis 53 ± 13 years. Bivariate, chi-square, analysis of variance and adjusted regression analyses were used. Results: In total, 115 diffuse cutaneous systemic sclerosis patients (63%) and 62 limited cutaneous systemic sclerosis (29%) received immunosuppressive drugs, most commonly methotrexate, followed by mycophenolate mofetil and cyclophosphamide. In diffuse cutaneous systemic sclerosis, immunosuppressants were prescribed after 2007 more often (74% vs 50%, p = 0.001), especially methotrexate ( p = 0.02) and mycophenolate mofetil ( p = 0.04), and earlier (peak at 2 years after onset). Immunosuppressive therapy was associated with male gender, interstitial lung disease, anti-Scl70 positivity, ACA negativity and inflammatory joint disease in limited cutaneous systemic sclerosis and with ACA negativity and a higher modified Rodnan skin score in diffuse cutaneous systemic sclerosis. Multivariate regression analysis showed that the use of immunosuppressants after 2007 was predicted only by ACA negativity in limited cutaneous systemic sclerosis and by younger age in diffuse cutaneous systemic sclerosis. Conclusion: Over the past decade, there has been a trend to prescribe immunosuppressants more often and earlier in diffuse cutaneous systemic sclerosis patients, regardless of modified Rodnan skin score. Methotrexate is being more frequently used, and mycophenolate mofetil has gained favour over cyclophosphamide. Autoantibody status was the most consistent predictor of immunosuppressive therapy.

Sign in / Sign up

Export Citation Format

Share Document